Activity and acceptability of piribedil in Parkinson's disease: a multicentre study.

摘要: Several controlled trials have shown that the dopamine agonist, Trivastal (piribedil), is active in treatment of Parkinson's disease, particularly with regard to tremor. To determine its efficacy as monotherapy patients previously untreated levodopa, a 3-month multicentre study was conducted 50 mg LP 113 idiopathic disease. The population consisted 66 men and 47 women, aged 63.1, SD 0.6 (43-79) years 2.1, 0.2 (1-15) year history Mean disease stage 1.82 (1-4) by Hoehn Yahr classification. Tremor predominant clinical feature 42 patients; remaining 71 displayed full parkinsonian syndrom. prescribed stepwise up doses 150-250 (207, 6.4) mg/day at end 3 months. No concomitant anti-parkinsonian medication given. Patients were clinically assessed 1, 2 months on Webster scale, specific tremor scale HARD depression scale. results follows 90 completing study. On fell from 1.7 1 (-41%, P less than 0.001), bradykinesia 1.5 0.8 (-47%, 0.001) rigidity 1.3 0.9 (-31%, 0.001); rest decreased daily duration amplitude 3.9 2.4 (-39%, 2.9 2.1 (-35%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)